Collaboration Revenue - Additional Information (Details) - USD ($) $ in Thousands			3 Months Ended		12 Months Ended
	Oct. 22, 2025	May 31, 2025	Dec. 31, 2025	Jun. 30, 2025	Dec. 31, 2025	Dec. 31, 2024
Disaggregation Of Revenue [Line Items]
Collaboration revenue					$ 27,466	$ 9,287
Short-term research and development contract liability			$ 5,335		5,335	85
Accounts receivable			5,546		5,546	945
Provision for income taxes					500	0
Prepaid expenses and other short-term assets			1,309		1,309	805
Accrued Liability			200		200
Other long-term assets			94		94	105
Collaboration Agreement with LG Chem Life Sciences \| LG Chem Life Sciences
Disaggregation Of Revenue [Line Items]
Milestone payments received					6,800
Collaboration revenue					0	100
Einstein License And Service Agreement
Disaggregation Of Revenue [Line Items]
Patent expenses				$ 900
Payment for License Agreement					1,500
BI Collaboration and License Agreement
Disaggregation Of Revenue [Line Items]
Up front non refundable payment			1,900		1,900
Upfront Payment				$ 10,100
Success-based research, development and commercial milestone payments					345,000
Collaboration revenue					8,100
Long-term research and development contract liability			5,300		5,300
Accounts receivable			500		500
BI Collaboration and License Agreement \| Einstein
Disaggregation Of Revenue [Line Items]
Patent expenses		$ 1,100			1,100
Prepaid expenses and other short-term assets			500		500
Amortization of Intangible Assets		$ 600
Collaboration and Option Agreement with Ono
Disaggregation Of Revenue [Line Items]
Collaboration revenue					400	9,200
Short-term research and development contract liability						$ 100
One time up front payment payable as consideration rd activities			$ 3,000		$ 3,000
First Research Term Processed Milestone Payment Under Agreement			18 months		18 months
Collaboration and Option Agreement with Ono \| Maximum
Disaggregation Of Revenue [Line Items]
Full time employe salary payable in first research term			$ 2,100		$ 2,100
Agreed To Increase Full Time Employee Salaries			3,100		3,100
ImmunoScape Collaboration and License Agreement
Disaggregation Of Revenue [Line Items]
Upfront Payment			15,000		15,000
Fair value of equity interest			3,900		3,900
Additional Time Based Payment					5,000
Collaboration revenue	$ 5,000		9,500		18,900
Accounts receivable			$ 5,000		5,000
Option Time Based Payment					$ 10,000
ImmunoScape Collaboration and License Agreement \| ImmunoScape Pte. Ltd.
Disaggregation Of Revenue [Line Items]
Percenatage of equity issued and outstanding			40.00%		40.00%

Cue Biopharma, Inc. 10-K